Survival based on current and revised ELN 2024 risk-stratification criteria. (A) Current ELN24 criteria risk stratify patients treated with HMA+VEN combinations in the US cohort with median OS of 17.2, 10.2, and 6.5 months across ELN24 favorable-, intermediate-, and adverse-risk groups, respectively. (B) Similar stratification was observed in patients treated with HMA+VEN combinations within the UK National Health Service (NHS) cohort. Notably, in both cohorts, 24-month OS was similar between favorable- and intermediate-risk patients. (C) Using the proposed revised ELN criteria improved OS stratification within the US cohort, with median OS across favorable-, intermediate-, and adverse-risk groups of 34.8 vs 13 vs 5.4 months, respectively. Survival stratification was notably improved between favorable- and intermediate-risk patients at 24 months (51% vs 35%). (D) Similar findings were observed within the UK NHS cohort, with improved survival stratification between favorable- and intermediate-risk groups (24-month OS, 43% vs 31%).